NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.

CompletedN/A

Sponsor: Pfizer

Conditions: Migraine

Countries: United States

This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Female or male patients with migraine ≥18 years old
* Having received a prescription for rimegepant for acute treatment
* Experienced between 3 and 14 Headache days in the last 30 days
* Planning to use rimegepant for attacks happening during the next 30 days

Exclusion Criteria:

* Report currently using rimegepant as preventive
* Report currently using concomitantly onabotulinumtoxin and any of the mAbs
* Currently participating in a Migraine-related clinical trial
* Reports a diagnosis from a doctor or other health professional of cluster headache, post-traumatic headache, new daily persistent headache, or hemicrania continua

Locations (1)

New York, New York, United States